Last update April 15, 2024

Καντεσαρτάνη σιλεξετίλη

Compatible

Safe substance and/or breastfeeding is the best option.

It is an angiotensin II receptor antagonist with actions similar to those of losartan. It is indicated in the treatment of hypertension and in heart failure. Oral administration once or twice a day.

Its pharmacokinetic data (high molecular weight and high percentage of plasma protein binding) explain the negligible passage into milk observed. (Coberger 2019)

The plasma levels of infants whose mothers take candesartan were indetectable. (Coberger 2019)

Its low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption.

Alternatives

  • Captopril (Safe substance and/or breastfeeding is the best option.)
  • Enalapril (Safe substance and/or breastfeeding is the best option.)
  • Quinapril Hydrochloride (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Καντεσαρτάνη σιλεξετίλη is Candesartan Cilexetil in Greek.

Is written in other languages:

Groups

Καντεσαρτάνη σιλεξετίλη belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Καντεσαρτάνη σιλεξετίλη in its composition:

List of 21 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 14 - 40 %
Molecular weight 611 daltons
Protein Binding 99 %
VD 0.1 l/Kg
pKa 3.44 -
Tmax 3 - 4 hours
T½ 9 hours
M/P ratio 0.02 -
Theoretical Dose 0.0001 - 0.00038 mg/Kg/d
Relative Dose 0.07 - 0.1 %

References

  1. Coberger ED, Jensen BP, Dalrymple JM. Transfer of Candesartan Into Human Breast Milk. Obstet Gynecol. 2019 Sep;134(3):481-484. Abstract
  2. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source)
  3. As.Zen. Candesartan. DrugSummary. 2013 Full text (in our servers)
  4. AEMPS. Candesartán. Ficha técnica. 2011 Full text (in our servers)
  5. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)

Total visits

1,274

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM